Ozempic bests dulaglutide in reducing heart attack, stroke and death risk

Continuing the upmanship battle in expanding the use of GLP-1 drugs beyond diabetes and obesity, Novo Nordisk (NOV: N) has released new data on use of its Ozempic (semaglutide).to reduce cardiovascular risks.

Novo Nordisk today announced results from the REACH real-world study, which demonstrated that compared to Eli Lilly’s (NYSE: LLY) Trulicity (dulaglutide) once-weekly injectable semaglutide was associated with a reduced risk of major dulaglutide

The data span nearly 60,000 US Medicare patients (aged ≥66 years) living with type 2 diabetes, atherosclerotic cardiovascular disease (ASCVD) – a condition where fatty deposits build up in blood vessels, reducing blood flow and increasing the risk of heart attacks, strokes and related problems – and multiple health conditions. The results were presented at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting  in Vienna, Austria.